Company news
Phio Pharmaceuticals Corp. news in 2025
Phio Pharmaceuticals Corp.'s news releases, calls and decks from 2025, newest first.
Phio Pharmaceuticals Announces Significant Step Forward in its Drug Development Program for PH-762
December 23, 2025
Phio Pharmaceuticals Announces Completion of Enrollment in Phase 1b Clinical Trial of INTASYL siRNA Lead Compound PH-762
November 25, 2025
Phio Pharmaceuticals Announces Upcoming Podium Presentation at the Advanced Therapies USA 2025 Congress
November 17, 2025
Phio Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update
November 13, 2025
Phio Pharmaceuticals to Present Recent Clinical Results from Skin Cancer Trial with siRNA based INTASYL PH-762
November 7, 2025
Phio Pharmaceuticals Announces INTASYL PH-762 is Named Immunomodulatory Solution of the Year in the BioTech Breakthrough Award Program
November 7, 2025
Phio Pharmaceuticals Announces Exercise of Warrants for Approximately $13.4 Million Gross Proceeds
November 3, 2025
Phio Pharmaceuticals Announces Positive Pathology Results: Final Maximum Dose Cohort for INTASYL PH-762 Skin Cancer Trial
November 3, 2025
Phio Pharmaceuticals Announces Appointment of Mr. David H. Deming to the Position of Lead Independent Director
October 31, 2025
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series
October 21, 2025
Phio Pharmaceuticals to Present at the Life Sciences Future Conference
September 18, 2025
Phio Pharmaceuticals to Present at the H.C. Wainwright 27th Annual Global Investment Conference
September 3, 2025
Phio Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update
August 14, 2025
Phio Pharmaceuticals Announces Exercise of Warrants for Approximately $2.5 Million Gross Proceeds
July 25, 2025
Phio Pharmaceuticals Announces Pathology Results for Four of Five Patients in Fourth Cohort
July 25, 2025
Phio Pharmaceuticals Announces Agreement with U.S. Manufacturing Source for Drug Substance
July 25, 2025
Phio Pharmaceuticals Announces Positive Safety Monitoring Committee Recommendation to Advance INTASYL PH-762 Skin Cancer Clinical Trial to Fifth Dose Escalation Cohort
June 25, 2025
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series
June 24, 2025
Phio Pharmaceuticals Announces Strategic Initiative to Create Awareness of the Comprehensive INTASYL siRNA Portfolio
June 6, 2025
Phio Pharmaceuticals Announces Participation in the Sidoti Micro-Cap Virtual Investor Conference
May 19, 2025
Phio Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update
May 15, 2025
Phio Pharmaceuticals Announces Positive Pathology Results in Third Cohort in INTASYL PH-762 Skin Cancer Clinical Trial
May 7, 2025
Phio Pharmaceuticals Announces Positive Safety Monitoring Committee Recommendation to Advance INTASYL PH-762 Skin Cancer Study to Fourth Dose Escalation Cohort
April 9, 2025
Phio Pharmaceuticals Announces Podium Presentations on INTASYL siRNA Lead Product Candidates PH-762 and PH-894
April 3, 2025
Phio Pharmaceuticals Reports 2024 Year End Financial Results and Provides Business Update
March 31, 2025
American Academy of Dermatology Awards Podium Presentation to Phio Pharmaceutical's Clinical Research at 2025 Annual Meeting
March 10, 2025
Phio Pharmaceuticals Announces Completion of Enrollment in Third Safety Cohort in PH-762 Phase 1b Dose-Escalation Study
March 5, 2025
Phio Pharmaceuticals Announces Appointment of David H. Deming to Board of Directors
February 20, 2025
Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series
January 21, 2025
Phio Pharmaceuticals Announces Closing of $1.83 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
January 20, 2025
Phio Pharmaceuticals Announces $1.83 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
January 15, 2025
Phio Pharmaceuticals Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
January 14, 2025
Phio Pharmaceuticals Announces $3.19 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
January 13, 2025
Phio Pharmaceuticals Announces Promising Results of Second Cohort from Its Ongoing Clinical Study of PH-762
January 12, 2025
Phio Pharmaceuticals Announces Publication in Clinical, Cosmetic and Investigational Dermatology
January 1, 2025